BioSpace News Archive

Feb. 24, 2020 13:00 UTC Conference Call and Webcast Scheduled for Monday, March 2, 2020 at 8:30 AM ET NEW YORK--( BUSINESS WIRE )-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will report fourth quarter and full year 2019 financial results on Monday, March 2, 2020, prior to the open of the market. The ann

ESCAPE Bio, Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that Julie Anne Smith, Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020.

Feb. 24, 2020 13:00 UTC Stoke Therapeutics to Present at 40 th Annual Cowen Health Care Conference BEDFORD, Mass.--( BUSINESS WIRE )-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 40 th Annual Cowen Health Care Conference on Monday, March 2, 2020 at 3:3

Corporate Headquarters Relocated to Lilly Gateway Labs in South San Francisco

Feb. 24, 2020 13:30 UTC Zymeworks to Present at Raymond James 41 st Annual Institutional Investors Conference VANCOUVER, British Columbia--( BUSINESS WIRE )-- Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional Investors Conference taking place March 1-4, 2020 in Orlando, FL. The Company’s presentation will be on Monday, March 2

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for QIXLEEF™ following the previously announced Letter of Advice and Type B meeting with the US Food and Drug Administration (FDA).

Combination of consultancy, training, robotics and newly-acquired patient optimization technologies to benefit patients and healthcare providers

Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.

NEW YORK , Feb. 24, 2020 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace . Albertsons Companies is one of the largest reta

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and CF Europe, the federation of 48 national CF Associations in Europe, today announced the completion of enrollment of 502 patients with CF for HIT-CF, a European-based initiative that is paving the path to personalized medicine through the CHOICES clinical trial.